Decreased Muscle Mass Linked with Higher Toxicity, Poorer Prognosis Risk in Colon Cancer
the Cancer Therapy Advisor take:
Decreased muscle mass is associated with an increased risk of grade 3/4 toxicity and poorer prognosis in patients with stage 3 colon cancer, according to a recent study published in Supportive Care in Cancer.
Korean researchers led by Hee-Won Jung, MD, at the Seoul National University College of Medicine examined data on 229 patients with stage 3 colon cancer who received adjuvant oxaliplatin, 5-fluorouracil, and leucovorin chemotherapy from 2003 to 2010, measuring for effects of muscle mass on toxicity and survival. Median age was 61 years and 134 patients were male.
The researchers found that decrease in muscle mass was associated with increased toxicity in all grade 3/4 cancers in univariate and multivariate analyses.
In multivariate analysis alone, they found that an incremental decrease in muscle mass index increased the hazard of overall mortality.
The effect was further confirmed in subgroup analyses and it was further pronounced in patients who were older and obese.
Decreased muscle mass is associated with an increased risk of grade 3/4 toxicity and poorer prognosis in stage 3 colon cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer